Ken Griffin Ligand Pharmaceuticals Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$82.7 - $110.11 $1.27 Million - $1.68 Million	-15,300 Reduced 58.62%	10,800 $1.08 Million
Q2 2024 Aug 14, 2024	BUY	$68.53 - $87.91 $116,501 - $149,447	1,700 Added 6.97%	26,100 $2.2 Million
Q1 2024 May 15, 2024	BUY	$68.64 - $89.2 $782,496 - $1.02 Million	11,400 Added 87.69%	24,400 $1.78 Million
Q4 2023 Feb 14, 2024	BUY	$49.57 - $72.63 $381,689 - $559,251	7,700 Added 145.28%	13,000 $928,000
Q3 2023 Nov 14, 2023	SELL	$58.86 - $72.67 $35,316 - $43,602	-600 Reduced 10.17%	5,300 $317,000
Q2 2023 Aug 14, 2023	BUY	$69.53 - $79.33 $62,577 - $71,397	900 Added 18.0%	5,900 $425,000
Q1 2023 May 15, 2023	SELL	$65.67 - $77.08 $118,206 - $138,744	-1,800 Reduced 26.47%	5,000 $367,000
Q4 2022 Feb 14, 2023	SELL	$61.72 - $96.74 $10.2 Million - $16 Million	-165,600 Reduced 96.06%	6,800 $454,000
Q3 2022 Nov 14, 2022	BUY	$0.01 - $107.56 $1,625 - $17.5 Million	162,500 Added 1641.41%	172,400 $14.8 Million

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.88B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.